25 April 2016 - Aralez Pharmaceuticals today announced the Health Canada approval of Blexten (bilastine 20 mg tablets) for the treatment of the symptoms of seasonal allergic rhinitis and chronic spontaneous urticaria.

The approval was granted to Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez formed under the laws of Ireland. Blexten will be distributed in Canada by Tribute Pharmaceuticals Canada Inc., also a subsidiary of the Company.

For more details, go to: http://ir.aralez.com/phoenix.zhtml?c=254163&p=RssLanding&cat=news&id=2160886